New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 14, 2014
08:32 EDTAZN, LGNDLigand signs research and licensing agreement with Omthera Pharmaceuticals
Ligand Pharmaceuticals (LGND) announced that it has entered into a licensing agreement and research collaboration with Omthera Pharmaceuticals, a wholly-owned subsidiary of AstraZeneca (AZN), for the development of products to treat dyslipidemia, including hypertriglyceridemia. The research collaboration will target the development of novel products that utilize the proprietary Ligand-developed LTP TECHNOLOGY to improve lipid-lowering activity of certain omega-3 fatty acids. Under the terms of the agreement, Ligand will be eligible to receive payments of up to $44.5M upon the achievement of specific milestones, as well as tiered royalties ranging from mid to high single digits of net sales. Omthera is solely responsible for all research and clinical development costs as well as commercialization of any product(s) derived from this collaboration.
News For LGND;AZN From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
December 1, 2015
14:54 EDTAZNAstraZeneca to hold a conference call
Chief Medical Officer Sean Bohen discusses key potential medicines within the late-stage pipeline and provides further details on progress made in 2015 and anticipated newsflow in 2016 on a conference call to be held on December 2 at 11 am. Webcast Link
11:51 EDTAZNAstraZeneca upgraded two notches to Overweight at Morgan Stanley
Subscribe for More Information
11:38 EDTAZNAstraZeneca upgraded to Overweight from Underweight at Morgan Stanley
Subscribe for More Information
07:46 EDTAZNFDA and the Parental Drug Association to co-host a conference
Subscribe for More Information
November 25, 2015
09:38 EDTLGNDLigand enters license and supply agreement with Vireo Health
Subscribe for More Information
November 23, 2015
07:59 EDTAZNPerrigo acquires Entocort from AstraZeneca for $380M
Subscribe for More Information
06:00 EDTAZNAstraZeneca sells U.S. Entocort drug rights to Perrigo for $380M
Subscribe for More Information
November 20, 2015
07:31 EDTAZNLabcyte, AstraZeneca partner to develop acoustic liquid handling system
Labcyte announced a partnership with AstraZeneca to develop a state-of-the-art automated pharmaceutical compound management system based on its revolutionary Echo acoustic liquid handling technology. The new system, which will employ storage tubes compatible with acoustic liquid handling, will be deployed at the AstraZeneca MRC UK Centre for Lead Discovery in Cambridge.
06:09 EDTAZNSanofi, AstraZeneca to exchange more than 210,000 compounds
Subscribe for More Information
November 18, 2015
16:43 EDTAZNBIND Therapeutics gets $4M milestone payment from AstraZeneca
Subscribe for More Information
14:43 EDTLGNDLigand management to meet with Craig-Hallum
Meeting to be held in Minneapolis on November 19 hosted by Craig-Hallum.
10:15 EDTLGNDLigand sees 2017 adjusted EPS over $4.75
Subscribe for More Information
10:12 EDTLGNDLigand reaffirms 2015 adjusted EPS outlook $3.34-$3.37
Subscribe for More Information
08:11 EDTAZNIMS Health forecasts global drug spending to increase 30% by 2020 to $1.4T
Subscribe for More Information
08:02 EDTAZNBIND says AstraZeneca initiates patient dosing in AZD2811 Phase 1 trial
Subscribe for More Information
07:26 EDTAZNZS Pharma downgraded to Neutral from Buy at Citi
Subscribe for More Information
November 17, 2015
11:25 EDTLGNDLigand to host analyst day
Analyst Day to be held in New York on November 17 at 10 am. Webcast Link
07:03 EDTAZNCerulean, AstraZeneca partner to evaluate LYNPARZA, CRLX101 combo
Cerulean (CERU) announced that it has entered into a collaboration with AstraZeneca (AZN) and the National Cancer Institute, part of the National Institutes of Health, to study LYNPARZA and CRLX101. The collaboration will explore the synergistic effects of AstraZeneca's LYNPARZA, a poly ADP ribose polymerase inhibitor, and CRLX101, Cerulean's inhibitor of topoisomerase 1. The NCI will conduct a combination Phase I/IIa trial in the Branch led by Yves Pommier, M.D., Ph.D., Chief of the Developmental Therapeutics Branch.
06:02 EDTAZNAstraZeneca drug to cost over $12K for a month's supply, Reuters reports
Subscribe for More Information
05:37 EDTAZNClovis downgraded to Neutral from Conviction Buy at Goldman
Goldman Sachs analyst Terence Flynn downgraded Clovis Oncology (CLVS) to Neutral from Conviction Buy citing limited visibility on the path to FDA approval following yesterday's update on the company's lung cancer drug Roci. The drug now has a less compelling profile relative to AstraZeneca's (AZN) Tagrisso, Flynn tells investors in a research note. He cut his price target for shares to $23 from $123. Clovis closed yesterday down $66.19, or 70%, to $30.24.

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the disclaimer & terms of use